Group 1 - In August 2025, the Hong Kong Stock Exchange (HKEX) saw 6 new IPOs raising a total of 53.86 billion HKD, with Tianyue Advanced and Jiaxin International Resources leading the fundraising efforts at 20.44 billion HKD and 13.79 billion HKD respectively [1][2] - The overall trend indicates a slowdown in IPO activity since June 2025, with only 58 new IPOs raising over 134.1 billion HKD from January to August 2025 [2][6] - As of August 31, 2025, there are 234 companies in the IPO queue on HKEX, with 124 on the main board and 5 having passed the hearing [1][6] Group 2 - Tianyue Advanced, listed on August 20, 2025, had an issue price of 42.8 HKD per share and saw a first-day closing increase of 6.4%, although its stock price has since declined to 44.1 HKD [5] - Silver Pharmaceutical, which focuses on diabetes and metabolic disease treatments, had an issue price of 18.68 HKD per share and experienced a first-day price surge of over 200%, but has since dropped to around 42 HKD [5] - Major companies like Luxshare Precision and others are continuing to pursue IPOs in Hong Kong, indicating ongoing interest in the "A+H" market strategy [9]

2025年以来，内地推进赴港上市的A股上市公司已有21家， 其中包括万亿市值的宁德时代（300750.SZ），千亿市值的海天味业（603288.SH）、恒 瑞医药（600276.SH）、三一重工（600031.SH）等。 这一数据远超去年同期。2024年前三个月，明确推进赴港上市且处于实质性进展的A股上市公司较少，有康乐卫士、迈威生物等。 具体来说，宁德时代是全球知名的新能源创新科技公司，已递交招股书。 赴港上市主要是为了进一步推进公司全球化战略布局，其港股 IPO 募集资金用 于推进匈牙利项目等。 海天味业是千亿市值的调味品行业龙头企业， 在推进赴港上市事宜以拓展国际市场，提升品牌的国际影响力。 恒瑞医药是千亿市值的医药生物领域巨头， 拟赴港上市以加强国际业务布局，提升公司在全球医药市场的竞争力。 晶澳科技是全球光伏一体化组件龙头之一， 2025年2月21日晚间公告计划发行境外上市外资股（H 股）股票并申请在香港联交所主板挂牌上市，旨在进一 步推动公司全球化发展战略。 三一重工是千亿市值的工程机械行业龙头企业， 2025年2月18日晚间公告称正在筹划境外发行股份（H 股）并在香港联合交易所有限公司上市事项， ...